Diagnostic Approach to Persistent Postpartum Anemia After LSCS

Laboratory Tests and Clinical Assessment

A peripheral blood smear should be performed to look for schistocytes, which indicate microangiopathic hemolysis, and a direct Coombs test should be done to exclude autoimmune hemolysis, according to the American College of Obstetricians and Gynecologists 1
Haptoglobin level and LDH level should be checked, as they will be low and elevated, respectively, if hemolysis is occurring, as recommended by the American College of Obstetricians and Gynecologists 1
Reticulocyte count should be assessed to evaluate bone marrow response, and ADAMTS13 activity level should be measured if TMA is suspected, as suggested by the American Society of Hematology 1
Fibrinogen level should be checked, as it should be 4-6 g/L in postpartum; <2 g/L suggests consumptive coagulopathy, according to the American College of Obstetricians and Gynecologists 2, 3
Cumulative blood loss should be measured using volumetric techniques, as visual estimation consistently underestimates actual loss, as recommended by the American College of Obstetricians and Gynecologists 4
Pelvic ultrasound should be performed to exclude retained products of conception, hematoma formation, or ongoing bleeding, as suggested by the American Institute of Ultrasound in Medicine 5
Shock Index should be calculated, as >1 indicates hemodynamic instability requiring immediate intervention, according to the American College of Surgeons 4

If schistocytes are absent and haptoglobin is normal, retained products of conception are high-risk in post-LSCS patients due to weakened cesarean scar, and transvaginal ultrasound with color Doppler should be used to identify vascular retained tissue, as recommended by the Society for Maternal-Fetal Medicine 5
If thrombocytopenia is worsening beyond day 5, with persistent hemolysis despite "resolved" labs, complement blockade with eculizumab should be initiated immediately for presumed aHUS, as suggested by the American Society of Hematology 1
aHUS has high mortality without complement blockade but excellent outcomes with eculizumab, according to the National Institutes of Health 1

Transfusion should be considered if Hb <7.0 g/dL regardless of symptoms, or if Hb 7.0-8.0 g/dL with cardiac disease or ongoing bleeding, as recommended by the American Association of Blood Banks 4
Each unit of transfused blood should increase Hb by approximately 1 g/dL, according to the American Red Cross 4
Iron replacement strategy should be based on the severity of anemia, with intravenous ferric iron 800-1500 mg for severe anemia, and oral ferrous iron 100-200 mg daily for mild-moderate anemia, as suggested by the American College of Obstetricians and Gynecologists 4